
    
      The following 3 pembrolizumab substudies will evaluate the efficacy of different
      investigational agents in combination with pembrolizumab given in sequence or in combination
      with pembrolizumab PLUS chemotherapy:

        -  KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational
           Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naïve Patients
           with Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A) - NCT04165070

        -  KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational
           Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive
           Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B) - NCT04165083

        -  KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study with Rolling Arms of Investigational
           Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung
           Cancer (NSCLC) Previously Treated with anti-PD-(L)1 Therapy (MK-3475-01C) - NCT04165096
    
  